Shocking doubts have emerged about the Oxford Covid-19 vaccine after it only worked well in younger age groups. Oxford University and pharma giant AstraZeneca announced to much fanfare this week that clinical trials were up to 90% effective.
However the group of trial participants who achieved this success rate had actually been given an initial half dose - a blunder first revealed by the Mirror in June.
The trial continued and the main group who were given two full doses only recorded an effectiveness rate of 62%. It has now emerged the smaller group of less than 3,000 out of 24,000 trial participants on the half-dose-full-dose regime - which recorded the 90% effectiveness rate - were all under 55.